---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-041646"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:31:38.376686+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M

## Summary
- Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.
- Amneal named Metsera's preferred supply partner for US and Europe; licensed to commercialize in select emerging markets.
- Metsera's lead candidate MET-097 (GLP-1 injectable) showed durable weight loss in Phase 1; expected first drug under collaboration.
- Collaboration leverages Amneal's existing manufacturing network and provides a new high-growth vector in the obesity market.

## SEC filing metadata
- accession: 0001628280-24-041646
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000162828024041646/0001628280-24-041646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000162828024041646/amrx-20241001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-041646
- JSON: https://secwatch.observer/filing/0001628280-24-041646.json
- Plain text: https://secwatch.observer/filing/0001628280-24-041646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.